Neurocrine Is Maintained at Buy by UBS
Ratings actions from Benzinga: GMT) Neurocrine Price Target Cut to $214.00/Share From $231.00 by UBSRatings actions from Benzinga
Related stories
Microsoft on outage: services across previously impacted environments have been restored
L impact | NEWS | Nov 14, 2026, 03:59 AM UTC
US Transportation Secretary Duffy: spoke with Trump
L impact | NEWS | Nov 14, 2026, 02:00 AM UTC
US transportation secretary duffy: communication and radar never fully went dark
L impact | NEWS | Nov 14, 2026, 01:53 AM UTC
US transportation secretary Duffy: Expect it will take some time to return to full capacity
L impact | NEWS | Nov 14, 2026, 01:48 AM UTC
US DHS Secretary Mullin: no evidence incident involved cyberattack or artificial intelligence
L impact | NEWS | Nov 14, 2026, 01:44 AM UTC
US DHS Secretary Mullin: still considering possibility of cyberattack, not dismissing it
L impact | NEWS | Nov 14, 2026, 01:42 AM UTC